sonlicromanol
Primary Mitochondrial Disease (m.3243A>G mutation) - MELAS, MIDD, CPEO, mixed phenotypes
Phase 3Active
Key Facts
Indication
Primary Mitochondrial Disease (m.3243A>G mutation) - MELAS, MIDD, CPEO, mixed phenotypes
Phase
Phase 3
Status
Active
Company
About Khondrion
Khondrion is a Netherlands-based, private, clinical-stage biotech company pioneering therapies for primary mitochondrial diseases. Its lead asset, sonlicromanol, is in late-stage development, with preparations underway for a registrational Phase 3 study targeting patients with the m.3243A>G mutation. Founded in 2013 by renowned mitochondrial disease expert Prof. Jan Smeitink, the company leverages proprietary science and a collaborative network, recently undergoing a leadership transition with Jasper Levink appointed as the new CEO to guide its next growth phase.
View full company profile